Issue 46, 2021

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

Abstract

We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.

Graphical abstract: In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

Supplementary files

Article information

Article type
Communication
Submitted
16 Dec 2020
Accepted
04 May 2021
First published
04 May 2021

Chem. Commun., 2021,57, 5678-5681

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

A. Steinbrueck, A. C. Sedgwick, H. Han, M. Y. Zhao, S. Sen, D. Huang, Y. Zang, J. Li, X. He and J. L. Sessler, Chem. Commun., 2021, 57, 5678 DOI: 10.1039/D0CC08156F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements